Business Context and Reporting Period
Tango Therapeutics, Inc. (TNGX) filed a Current Report on Form 8-K dated November 18, 2025, with the earliest event reported on November 21, 2025. The filing details the termination of an existing equity sales agreement and the simultaneous entry into a new "at-the-market" (ATM) offering program.
Key Financial Metrics and Capital Structure
This filing does not report operational financial metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to capital raising capacity:
- New ATM Program Capacity: Up to $100,000,000 in common stock.
- Sales Agent Commission: Up to 3.0% of the gross sales price per share.
- Termination Penalties: None associated with the termination of the prior agreement.
Material Changes Versus Prior Period
The Company executed a material change in its equity distribution strategy:
- Termination of Prior Agreement: The Company terminated its Open Market Sales Agreement with Jefferies LLC (the "2022 ATM Program"), effective November 21, 2025. No further shares will be sold under this program.
- Entry into New Agreement: On November 21, 2025, the Company entered into a new Sales Agreement with Leerink Partners LLC to serve as the sales agent for the new ATM Offering.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The Company retains the option to sell shares under the new agreement from time to time based on market conditions and Company instructions. However, the filing explicitly states that the Company cannot provide assurances that it will issue any shares pursuant to the Sales Agreement.
Risks and Contingencies: The sale of shares is subject to customary parameters, including price, time, or size limits imposed by the Company. The offering is not an offer to sell in any state where such an offer would be unlawful prior to registration.
Key Facts for Investor Verification
- Verify the effective date of the new ATM program (November 21, 2025) and the immediate cessation of the Jefferies program.
- Confirm the total aggregate offering limit of $100,000,000 under the new Leerink Partners agreement.
- Note the 3.0% commission fee payable to the sales agent on any shares sold.
- Review the attached Prospectus Supplement (filed November 21, 2025) for specific terms regarding the issuance of shares.